AnaptysBioANAB
ANAB
About: AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Employees: 136
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
150% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 5 (+3) [Q1 2025]
73% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 26
58% more capital invested
Capital invested by funds: $469M [Q4 2024] → $743M (+$274M) [Q1 2025]
13.89% more ownership
Funds ownership: 116.39% [Q4 2024] → 130.28% (+13.89%) [Q1 2025]
13% more funds holding
Funds holding: 135 [Q4 2024] → 153 (+18) [Q1 2025]
11% more call options, than puts
Call options by funds: $5.68M | Put options by funds: $5.12M
2% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 43
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$38
63%
upside
Avg. target
$56
140%
upside
High target
$90
286%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Emily Bodnar | 63%upside $38 | Buy Upgraded | 4 Jun 2025 |
Guggenheim Yatin Suneja | 286%upside $90 | Buy Maintained | 28 May 2025 |
Wedbush Martin Fan | 72%upside $40 | Outperform Reiterated | 1 May 2025 |
Financial journalist opinion
Based on 5 articles about ANAB published over the past 30 days
Positive
Seeking Alpha
5 days ago
AnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster Potential
Rosnilimab's strong Phase IIb RA data shows sustained efficacy and safety, positioning it as a potential blockbuster in a massive RA market. Despite JNJ's class setback, AnaptysBio offers significant upside, with fair value estimates nearly double its current market cap if RA approval is secured. Key risks include future cash needs, execution challenges, and tough competition, so I maintain a 2/5 conviction and keep ANAB in my speculative portfolio.
Positive
Seeking Alpha
1 week ago
AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement
AnaptysBio, Inc.'s rosnilimab showed strong phase 2b results in moderate-to-severe RA, achieving key efficacy and safety endpoints, supporting its potential in a $20B U.S. market. Rosnilimab is also being evaluated in a phase 2 trial for moderate-to-severe ulcerative colitis, targeting a $15.8B global market, with data expected in Q4 2025. ANAB has sufficient cash for at least 12 months but may need to raise additional funds, potentially via an existing $100M ATM agreement.
Positive
Benzinga
1 week ago
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point
AnaptysBio, Inc. ANAB on Tuesday released updated data from the Phase 2b trial of rosnilimab, a PD-1 depleter and agonist, for rheumatoid arthritis.
Neutral
GlobeNewsWire
1 week ago
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that investigational rosnilimab, a depleter and agonist targeting PD-1+ T cells, demonstrated a best-in-disease profile in patients with moderate-to-severe rheumatoid arthritis (RA). In the robust, global 424-patient Phase 2b trial, rosnilimab achieved JAK-like efficacy on multiple clinically meaningful measures, including low disease activity (LDA) and remission on the Clinical Disease Activity Index (CDAI), as well as ACR70 response, over a six-month period. Furthermore, responses were then durable for at least two months off drug. Rosnilimab was safe and well tolerated, particularly when compared to standard of care biologics or JAKs.
Neutral
GlobeNewsWire
2 weeks ago
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review updated data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist targeting PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Tuesday, June 3, 2025, at 4:15pm ET / 1:15pm PT.
Negative
Zacks Investment Research
1 month ago
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.30. This compares to loss of $1.64 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update
SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.
Positive
Zacks Investment Research
2 months ago
AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last?
AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Neutral
GlobeNewsWire
2 months ago
Anaptys Announces Stock Repurchase Plan
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company's outstanding common stock, par value $0.001 per share.
Negative
Zacks Investment Research
3 months ago
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $1.61. This compares to loss of $1.59 per share a year ago.
Charts implemented using Lightweight Charts™